Vancomycin to Prevent Recurrent C. difficile Infection This feature about a patient recently treated for C. difficile infection who now needs intravenous antibiotics offers a case vignette accompanied by two essays, one supporting use of oral vancomycin for C. difficile prophylaxis and the other not ...
206Oral Vancomycin Prophylaxis for the Primary and Secondary Prevention of Clostridium difficile Infection: A Systematic Review and Meta-Analysisdoi:10.14309/01.ajg.0000590356.40573.7cEl Kurdi, BaraEl Iskandarani, MahmoudBabar, SumbalHaddad, Ibrahim...
Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.doi:10.1177/1060028018815170Chase C BrownMelanie M ManisNicole M BohmScott R CurrySAGE PublicationsSage CA: Los Angeles, CA
Evaluations of oral vancomycin prophylaxis (OVP) against Clostridioides difficile have been reported in stem cell transplant populations with short follow-up periods. The longest known duration of standardized follow-up post-OVP is 90 days within an allogeneic stem cell transplant population. In ...
In this study, our primary objective was to evaluate the effectiveness and safety of an oral vancomycin prophylaxis (OVP) protocol for secondary prevention of CDI in a retrospective cohort of adult autologous/allogeneic HSCT recipients and patients with HM who did not undergo HSCT with a first ...
Does Oral Vancomycin Prophylaxis for Clostridium Difficile Infection Improve Allogeneic Hematopoietic Stem Cell Transplant Outcomes?doi:10.1016/j.bbmt.2016.12.615Pereiras, Maribel A.Urnoski, EricWynd, MichaelCicogna, CristinaSebti, RaniMcCoy, Dorothy...
1376. Oral Vancomycin as Secondary Prophylaxis Against Clostridioides difficile Infection in Pediatric PatientsHongkai Bao, PharMDYanina Dubrovskaya, PharMD, BCPS, BCIDP, AAHIVPJohn Papadopoulos, B.S., PharMD, FCCM, BCCCP, BCNSPJustin Siegfried, PharMD, BCPS...
A Case of Successfully Treated Central Line-Associated Bloodstream Infection Due to Vancomycin-Resistant Leuconostoc Citreum in a Child With Biliary Atresia. Cureus 2022, 14, 12–15. [Google Scholar] [CrossRef] Omori, R.; Fujiwara, S.; Ishiyama, H.; Kuroda, H.; Kohara, N. Leuconostoc ...
[195]. This polycyclic peptide displays a comparable activity to that of vancomycin against MRSA (methicillin-resistant S. aureus) without cross-resistance [196]. Bee and wasp venoms have three valuable peptides for therapeutics: melittin, apamin, and mastoparan (MP) [197]. MP with significant...
Additionally, studies have demonstrated that oral vancomycin has a significant impact on the host microbiota.#The mostly retrospective and heterogeneous nature of the currently available evidence makes it difficult to draw definitive conclusions as to when OVP should be utilized and who may benefit most...